Coronary Artery Disease

FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Jan 16, 2014
popularity not rated yet | comments 0

Latest Spotlight News

Research reveals how lymph nodes expand during disease

Cancer Research UK and UCL scientists have discovered that the same specialised immune cells that patrol the body and spot infections also trigger the expansion of immune organs called lymph nodes, according to a study published ...